Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Kalinich M, et al. Among authors: reynolds kl. J Immunother Cancer. 2021 Mar;9(3):e001935. doi: 10.1136/jitc-2020-001935. J Immunother Cancer. 2021. PMID: 33789879 Free PMC article.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Criss SD, et al. Among authors: reynolds kl. JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449. JAMA Oncol. 2019. PMID: 30543349 Free PMC article.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.
Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Leaf RK, et al. Among authors: reynolds kl. Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13. Am J Hematol. 2019. PMID: 30790338 Free PMC article. Clinical Trial.
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study.
Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Molina GE, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2020 Mar;82(3):743-746. doi: 10.1016/j.jaad.2019.07.049. Epub 2019 Jul 23. J Am Acad Dermatol. 2020. PMID: 31349048 Free PMC article. No abstract available.
Diagnosis and Management of Rare Immune-Related Adverse Events.
Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Schoenfeld SR, et al. Among authors: reynolds kl. Oncologist. 2020 Jan;25(1):6-14. doi: 10.1634/theoncologist.2019-0083. Epub 2019 Nov 6. Oncologist. 2020. PMID: 31694890 Free PMC article.
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.
Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O'Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG. Awadalla M, et al. Among authors: reynolds kl. J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049. J Am Coll Cardiol. 2020. PMID: 32029128 Free PMC article.
190 results